监狱环境中的疫苗接种:欧盟/欧洲经济区及其他高收入国家现状的系统综述
该研究系统检索1980至2016年文献,评估欧盟/欧洲经济区及其他高收入国家监狱疫苗接种的接受度、接种率、成本效果与障碍。监狱疫苗接种存在重要知识缺口与实施挑战。
要点
- 监狱人群疫苗接种接受度和接种率差异大,甲肝疫苗接受度5-91%、接种率62.9-70.5%。
- 乙肝疫苗第三剂非常快速方案接种率63%,显著高于标准方案20%。
- 未接种主因包括出狱或转监及拒绝,需定制化实施策略。
核心结论
- 监狱疫苗接种存在重要知识缺口和操作挑战,需全面定制化实施以降低可预防疾病负担并促进健康公平。
研究设计与样本
- 系统综述检索1980至2016年同行评议和灰色文献,纳入19篇同行评议全文和2篇灰色文献。
主要发现
- 两项甲肝疫苗研究报告接受度5-91%、接种率62.9-70.5%。
- 七项乙肝疫苗研究报告接受度54-100%,接种率第1剂23-100%、第2剂48-92%、第3剂19-80%。
- 一项甲乙肝联合疫苗研究报告接受度34%,接种第1剂后接种率下降。
- 一项流感疫苗研究报告接种率42-46%,另一项报告MMR疫苗接受度80%、接种率74%。
- 一项比较研究显示乙肝疫苗第三剂非常快速方案接种率63%,显著高于标准方案20%。
临床怎么用
- 针对监狱人群应实施定制化疫苗接种策略,并关注出狱或转监导致的接种中断问题。
局限性
- 纳入研究数量有限且以甲肝/乙肝疫苗为主,其他疫苗证据不足,存在知识缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In 2016, more than 600,000 persons were being held in EU/EEA correctional facilities on a given day. People in prison may be at risk of vaccine-preventable diseases. While vaccination recommendations for people in prison exist, little is known on coverage and implementation options. METHODS: We performed a systematic review on existing evidence on vaccination in prison settings in the EU/EEA. We searched peer-reviewed and grey literature following international methodology and reporting standards, to gather records published between 1980 and 2016 in all languages. We analysed quantitative (acceptance, uptake, cost-effectiveness) and qualitative (barriers) outcomes. RESULTS: Out of 7041 identified records, 19 full-text articles were included from peer-reviewed literature and two from grey literature. Of these, 18 reported on hepatitis A and/or B virus (HAV/HBV), two on influenza and one on MMR vaccination. Two studies on HAV vaccine reported varying acceptance (5-91%) and uptake rates (62.9-70.5%). Seven studies reported on HBV vaccination. A comparative study showed a significantly higher uptake of the third HBV vaccine dose with the very rapid (63%) compared to the standard schedule (20%). HBV vaccination was generally well accepted (54-100%), whereas uptake was variable (dose 1:23-100%, dose 2:48-92%, dose 3:19-80%). One study on the combined HAV/HBV vaccine reported an acceptance rate of 34%, and declining uptake following dose 1. One study on influenza vaccine showed an uptake of 42-46%, while another reported a MMR vaccine acceptance of 80% and an uptake of 74%. Overall, main reasons for non-vaccination included release from/or transfer between prisons, and refusal. CONCLUSIONS: This systematic review highlighted important knowledge gaps and operational challenges for vaccination in prison settings. Vaccination is an effective measure that warrants comprehensive and tailored implementation to reduce the preventable disease burden, avoid risks of large outbreaks of vaccine-preventable diseases, and contribute to health equity for people in prison.
引用
- Madeddu G, Vroling H, Oordt-Speets A, et al. Vaccinations in prison settings: A systematic review to assess the situation in EU/EEA countries and in other high income countries. Vaccine. 2019. PMID: 31327651. doi:10.1016/j.vaccine.2019.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。